Dr. Augusto Ochoa

Allergy and Immunology
Office
1700 Tulane Ave Fl 9, 
New Orleans, LA 
Office
1700 Tulane Ave Fl 9, 
New Orleans, LA 

Overview

Augusto Ochoa is an Allergy and Immunologist in New Orleans, Louisiana. His top areas of expertise are Asthma, Pulmonary Fibrosis, and Gallbladder Disease.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 58 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Allergy and Immunology

Licenses

Pediatric Allergy/Immunology in LA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Office
1700 Tulane Ave Fl 9, New Orleans, LA 70112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

58 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Cancer Moonshot Biobank Research Protocol
Cancer Moonshot Biobank Research Protocol
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Other
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
View 9 Less Clinical Trials

64 Total Publications

Community Factors and County-Level Cancer Screening, Prevalence, and Mortality.
Community Factors and County-Level Cancer Screening, Prevalence, and Mortality.
Journal: JAMA network open
Published: October 23, 2025
Similar Doctors
Expertise in
2
conditions
Dr. Kenneth Paris
Allergy and Immunology
Expertise in
2
conditions
Dr. Kenneth Paris
Allergy and Immunology

Children's Hospital New Orleans

200 Henry Clay Ave, 
New Orleans, LA 
 (0.1 miles away)
504-896-9589
Languages Spoken:
English
See accepted insurances

Kenneth Paris is an Allergy and Immunologist in New Orleans, Louisiana. Dr. Paris is highly rated in 2 conditions, according to our data. His top areas of expertise are Primary Immunodeficiency (PID), Asthma, Common Variable Immune Deficiency, and Autosomal Dominant Hyper IgE Syndrome.

Expertise in
13
conditions
Dr. Tammy Harvey
Allergy and Immunology
Expertise in
13
conditions
Dr. Tammy Harvey
Allergy and Immunology

The Family Asthma Allergy And Immunology Clinic

3321 W Esplanade Ave S, 
Metairie, LA 
 (6.8 miles away)
504-266-2444
Languages Spoken:
English
See accepted insurances

Tammy Harvey is an Allergy and Immunologist in Metairie, Louisiana. Dr. Harvey is highly rated in 13 conditions, according to our data. Her top areas of expertise are Primary Immunodeficiency (PID), Immunodeficiency with Hyper IgM Type 1, Sinusitis, and Allergic Rhinitis.

Expertise in
12
conditions
Dr. Irum Qureshi
Allergy and Immunology
Expertise in
12
conditions
Dr. Irum Qureshi
Allergy and Immunology

Asthma, Allergy & Immunology, LLC

160 Greenbrier Blvd, 
Covington, LA 
 (37.3 miles away)
985-893-5780
Languages Spoken:
English
See accepted insurances

Irum Qureshi is an Allergy and Immunologist in Covington, Louisiana. Dr. Qureshi is highly rated in 12 conditions, according to our data. Her top areas of expertise are Common Variable Immune Deficiency, Primary Immunodeficiency (PID), Grass Allergy, and Sinusitis.

Frequently Asked Questions about Dr. Augusto Ochoa

How do I make an appointment with Dr. Augusto Ochoa?

You can book an appointment with Dr. Augusto Ochoa by calling their office at 504-210-2828. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Augusto Ochoa a top-rated expert for Asthma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Augusto Ochoa is classified as an Experienced expert for Asthma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Augusto Ochoa specialize in?

While Dr. Augusto Ochoa is a Allergy and Immunology, they have specific expertise in Asthma, Pulmonary Fibrosis, and Gallbladder Disease. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Allergy and Immunology.

Does Dr. Augusto Ochoa participate in research or clinical trials?

Yes. Dr. Augusto Ochoa has published 64 articles and abstracts on conditions like Asthma. You can view a list of Dr. Augusto Ochoa's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Augusto Ochoa accept my insurance?

Dr. Augusto Ochoa accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 504-210-2828 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ochoa's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile